Advertisement
Canada markets open in 5 hours 48 minutes
  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CAD/USD

    0.7301
    +0.0000 (+0.00%)
     
  • CRUDE OIL

    82.22
    +0.32 (+0.39%)
     
  • Bitcoin CAD

    90,612.80
    +37.92 (+0.04%)
     
  • CMC Crypto 200

    1,397.48
    -17.28 (-1.22%)
     
  • GOLD FUTURES

    2,321.80
    -24.60 (-1.05%)
     
  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     
  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     
  • NASDAQ futures

    17,362.75
    +12.75 (+0.07%)
     
  • VOLATILITY

    16.69
    -0.25 (-1.47%)
     
  • FTSE

    8,066.33
    +42.46 (+0.53%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6831
    -0.0019 (-0.28%)
     

Can CureVac Win Market Share With Only 48% Vaccine Efficacy?

Can CureVac Win Market Share With Only 48% Vaccine Efficacy?

CureVac (NASDAQ: CVAC) surprised investors a few weeks ago when it announced disappointing data from a trial of its mRNA vaccine candidate. Many expected the German biotech would follow in the footsteps of fellow mRNA vaccine makers Pfizer and Moderna. After the CureVac report, it looked like company's dreams of a spot in the vaccine market were over -- at least in the near term.